List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8473936/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. New England Journal of Medicine, 2009, 361, 1164-1172.	27.0	1,054
2	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2020, 21, 671-684.	10.7	923
3	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 180-188.	2.6	647
4	lvosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 796-807.	10.7	620
5	Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. Journal of Clinical Oncology, 2010, 28, 4877-4883.	1.6	552
6	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Journal of Clinical Oncology, 2018, 36, 276-282.	1.6	524
7	Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2011, 17, 2502-2511.	7.0	499
8	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 541-565.	4.9	477
9	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. British Journal of Cancer, 2020, 122, 1630-1637.	6.4	472
10	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	6.4	416
11	Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. JAMA Oncology, 2019, 5, 824.	7.1	335
12	The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 2003, 9, 1136-44.	7.0	312
13	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nature Medicine, 2020, 26, 878-885.	30.7	297
14	Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. PLoS Genetics, 2014, 10, e1004135.	3.5	292
15	Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature, 2019, 567, 249-252.	27.8	263
16	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	1.6	257
17	Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Human Pathology, 2014, 45, 1630-1638.	2.0	235
18	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. The Lancet Gastroenterology and Hepatology, 2021, 6, 803-815.	8.1	205

MITESH J BORAD

#	Article	IF	CITATIONS
19	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. JAMA Oncology, 2021, 7, 1669.	7.1	194
20	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2021, 22, 1290-1300.	10.7	178
21	Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 1475-1481.	1.6	152
22	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses Journal of Clinical Oncology, 2017, 35, 4073-4073.	1.6	133
23	Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2011, 17, 2997-3004.	7.0	132
24	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. JAMA Oncology, 2020, 6, e204930.	7.1	124
25	ILâ€33 facilitates oncogeneâ€induced cholangiocarcinoma in mice by an interleukinâ€6â€sensitive mechanism. Hepatology, 2015, 61, 1627-1642.	7.3	115
26	ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances, 2021, 7, eabl8213.	10.3	112
27	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. Journal of Gastrointestinal Oncology, 2018, 9, 1054-1062.	1.4	110
28	Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities. Seminars in Liver Disease, 2014, 34, 456-464.	3.6	106
29	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements. Future Oncology, 2020, 16, 2385-2399.	2.4	96
30	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	1.6	96
31	Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology, 2018, 67, 2338-2351.	7.3	92
32	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. JCO Precision Oncology, 2018, 2, 1-12.	3.0	86
33	Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. Molecular Cancer Therapeutics, 2016, 15, 439-447.	4.1	85
34	Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 1092-1100.	7.0	78
35	Second-line therapies in advanced biliary tract cancers. Lancet Oncology, The, 2020, 21, e29-e41.	10.7	77
36	Immunotherapy in pancreatic cancer treatment: a new frontier. Therapeutic Advances in Gastroenterology, 2017, 10, 168-194.	3.2	73

#	Article	IF	CITATIONS
37	Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Letters, 2016, 380, 163-173.	7.2	72
38	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. JAMA Oncology, 2020, 6, e194489.	7.1	65
39	Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: AÂpropensity score matched analysis. European Journal of Surgical Oncology, 2019, 45, 1432-1438.	1.0	63
40	FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers, 2021, 13, 2968.	3.7	63
41	Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Rodents and Nonhuman Primates. Human Gene Therapy, 2010, 21, 451-462.	2.7	62
42	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget, 2017, 8, 27145-27154.	1.8	55
43	Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. British Journal of Cancer, 2018, 118, 153-161.	6.4	51
44	A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors. Clinical Cancer Research, 2013, 19, 268-278.	7.0	48
45	Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. Yale Journal of Biology and Medicine, 2009, 82, 1-6.	0.2	46
46	Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Investigational New Drugs, 2014, 32, 710-716.	2.6	44
47	Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. Current Opinion in Gastroenterology, 2015, 31, 264-268.	2.3	44
48	Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (<i>IDH1</i>) mutation Journal of Clinical Oncology, 2021, 39, 266-266.	1.6	41
49	Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 1002-1009.	7.0	39
50	Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study). International Journal of Surgery, 2018, 52, 171-179.	2.7	38
51	Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. Translational Oncology, 2019, 12, 143-153.	3.7	37
52	Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular–clinical analysis and potential targeted approach. Hepatology International, 2019, 13, 490-500.	4.2	36
53	Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas. Cancer Research, 2020, 80, 4324-4334.	0.9	36
54	Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. Clinical Gastroenterology and Hepatology, 2022, 20, e508-e528.	4.4	36

#	Article	IF	CITATIONS
55	Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precision Oncology, 2020, 4, 557-569.	3.0	35
56	FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. Journal of Hepatology, 2021, 75, 351-362.	3.7	35
57	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surgery and Nutrition, 2019, 8, 604-614.	1.5	34
58	Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut, 2022, 71, 185-193.	12.1	34
59	A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (<i>FGFR2</i>) gene rearrangements (FOENIX-CCA3) Journal of Clinical Opcology, 2020, 38, TPS600,TPS600	1.6	34
60	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Scientific Reports, 2016, 6, 25.	3.3	32
61	Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. Oncolytic Virotherapy, 2017, Volume 6, 39-49.	6.0	32
62	Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virotherapy, 2017, Volume 6, 11-18.	6.0	32
63	Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Investigational New Drugs, 2012, 30, 2334-2343.	2.6	31
64	Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 554-561.	1.4	31
65	A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. Investigational New Drugs, 2019, 37, 684-692.	2.6	30
66	Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 3431-3442.	7.0	29
67	Secondâ€line treatment in patients with pancreatic ductal adenocarcinoma: A metaâ€analysis. Cancer, 2017, 123, 4680-4686.	4.1	29
68	Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 73, 931-941.	2.3	28
69	Emerging role of precision medicine in biliary tract cancers. Npj Precision Oncology, 2018, 2, 21.	5.4	27
70	HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma. Hepatology, 2019, 69, 131-142.	7.3	27
71	The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?. Journal of Gastrointestinal Oncology, 2016, 7, 789-796.	1.4	26
72	Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Targeted Oncology, 2017, 12, 201-209.	3.6	25

#	Article	IF	CITATIONS
73	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. Cancers, 2022, 14, 2056.	3.7	24
74	Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer. Mayo Clinic Proceedings, 2017, 92, 1583-1591.	3.0	23
75	Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations. Journal of Clinical Medicine, 2017, 6, 26.	2.4	23
76	Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Oncologist, 2021, 26, 569-578.	3.7	23
77	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncology, 2018, 14, 553-566.	2.4	22
78	E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. Investigational New Drugs, 2019, 37, 636-645.	2.6	22
79	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Investigational New Drugs, 2022, 40, 134-141.	2.6	21
80	Oncolytic viruses: perspectives on clinical development. Current Opinion in Virology, 2015, 13, 55-60.	5.4	19
81	Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. International Journal of Clinical Oncology, 2013, 18, 934-941.	2.2	17
82	Feasibility of circulating tumor DNA testing in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 745-750.	1.4	17
83	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology, 2020, 20, 101-109.	1.1	17
84	Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Clinical and Translational Gastroenterology, 2021, 12, e00414.	2.5	17
85	Prevalent hepatitis B surface antigen among first-time blood donors in Gabon. PLoS ONE, 2018, 13, e0194285.	2.5	16
86	Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study. British Journal of Cancer, 2018, 118, 1580-1585.	6.4	16
87	Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. JCO Precision Oncology, 2021, 5, 432-441.	3.0	16
88	The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials. Journal of Cancer, 2012, 3, 345-353.	2.5	15
89	Genomic Medicine and Incidental Findings: Balancing Actionability and Patient Autonomy. Mayo Clinic Proceedings, 2014, 89, 718-721.	3.0	15
90	Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature Review. Case Reports in Gastroenterology, 2017, 10, 605-612.	0.6	15

#	Article	IF	CITATIONS
91	Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer. Hpb, 2020, 22, 1490-1495.	0.3	15
92	Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. European Journal of Surgical Oncology, 2020, 46, 789-795.	1.0	15
93	Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements. PLoS ONE, 2014, 9, e87113.	2.5	14
94	Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 1063-1078.	2.3	14
95	FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with <i>FGFR2</i> fusions or rearrangements Journal of Clinical Oncology, 2020, 38, TPS592-TPS592.	1.6	14
96	Marantic Endocarditis Associated with Pancreatic Cancer: A Case Series. Case Reports in Gastroenterology, 2009, 3, 67-71.	0.6	13
97	Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples. BMC Cancer, 2018, 18, 738.	2.6	13
98	Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. Genome Biology, 2021, 22, 227.	8.8	13
99	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Pancreatology, 2020, 20, 1115-1122.	1.1	12
100	Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond. Expert Opinion on Investigational Drugs, 2022, 31, 125-131.	4.1	12
101	Oncolytic virotherapy in upper gastrointestinal tract cancers. Oncolytic Virotherapy, 2017, Volume 7, 13-24.	6.0	11
102	Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. Hpb, 2019, 21, 379-386.	0.3	11
103	Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy. JCO Precision Oncology, 2021, 5, 733-743.	3.0	11
104	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2021, , .	1.1	11
105	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precision Oncology, 2022, , .	3.0	11
106	Using NaÃ ⁻ ve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. Diagnostics, 2017, 7, 50.	2.6	10
107	MetaMarker: a pipeline for <i>de novo</i> discovery of novel metagenomic biomarkers. Bioinformatics, 2019, 35, 3812-3814.	4.1	10
108	Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist, 2020, 25, 380-e763.	3.7	10

#	Article	IF	CITATIONS
109	Advances in the treatment of biliary tract cancers. Current Opinion in Gastroenterology, 2020, 36, 1.	2.3	10
110	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. Seminars in Liver Disease, 2021, 41, 136-141.	3.6	10
111	Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates. Critical Reviews in Oncology/Hematology, 2021, 168, 103535.	4.4	10
112	Isocitrate Dehydrogenase–Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precision Oncology, 2022, 6, e2100156.	3.0	10
113	Exploring the role of oncolytic viruses in hepatobiliary cancers. Immunotherapy, 2018, 10, 971-986.	2.0	9
114	Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. Hepatology Communications, 2020, 4, 1781-1792.	4.3	9
115	Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. Molecular Therapy - Oncolytics, 2020, 18, 546-555.	4.4	9
116	Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study. Cancer Prevention Research, 2022, 15, 121-128.	1.5	9
117	A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m ² Administered Weekly as a 30â€Minute Intravenous Infusion in Patients With Cancer. Journal of Clinical Pharmacology, 2010, 50, 268-275.	2.0	8
118	Oncolytic Adenoviruses in Gastrointestinal Cancers. Biomedicines, 2018, 6, 33.	3.2	8
119	Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. Chinese Clinical Oncology, 2021, 10, 11-11.	1.2	8
120	Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas cancer. Journal of Gastrointestinal Oncology, 2013, 4, 352-60.	1.4	8
121	Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Frontiers in Oncology, 2021, 11, 794009.	2.8	8
122	Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. Expert Opinion on Investigational Drugs, 2022, 31, 1-13.	4.1	8
123	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications, 2021, 12, 1930.	12.8	7
124	Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials. Investigational New Drugs, 2013, 31, 1056-1065.	2.6	6
125	Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy, 2018, 10, 1077-1091.	2.0	6
126	Synergistic combination of cytotoxic chemotherapy and cyclinâ€dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology, 2022, 75, 43-58.	7.3	6

MITESH J BORAD

#	Article	IF	CITATIONS
127	Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. Journal of Gastrointestinal Oncology, 2022, 13, 288-297.	1.4	6
128	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. Future Oncology, 2014, 10, 1255-1275.	2.4	5
129	Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy. Mayo Clinic Proceedings, 2020, 95, 306-318.	3.0	5
130	Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement Journal of Clinical Oncology, 2019, 37, TPS462-TPS462.	1.6	5
131	Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials. Cancer, 2011, 117, 3276-3283.	4.1	4
132	A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma. Cancer Investigation, 2015, 33, 172-179.	1.3	4
133	Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. Anti-Cancer Drugs, 2017, 28, 127-132.	1.4	4
134	Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells. Journal of Hepatology, 2020, 73, S122.	3.7	4
135	Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Investigational New Drugs, 2021, 39, 1072-1080.	2.6	4
136	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Digestive Diseases and Sciences, 2022, 67, 3797-3805.	2.3	4
137	Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precision Oncology, 2022, , .	3.0	4
138	Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. Clinical Genitourinary Cancer, 2017, 15, e727-e734.	1.9	3
139	Quantitative Imaging System for Cancer Diagnosis and Treatment Planning: An Interdisciplinary Approach. , 2017, , 152-175.		3
140	Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers, 2021, 13, 1186.	3.7	3
141	A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. Investigational New Drugs, 2022, 40, 81-90.	2.6	3
142	Targeting hyaluronan (HA) in tumor stroma: Interim safety and translational evaluation of pegylated hyaluronidase (PEGPH20) in patients (pts) with advanced solid tumors—A focus on gastrointestinal malignancies Journal of Clinical Oncology, 2012, 30, 249-249.	1.6	3
143	Reply to M. Buyse et al. Journal of Clinical Oncology, 2011, 29, e453-e453.	1.6	2
144	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Investigational New Drugs, 2016, 34, 96-103.	2.6	2

#	Article	IF	CITATIONS
145	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology, 2021, 5, 1228-1240.	3.0	2
146	P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer. Annals of Oncology, 2021, 32, S333.	1.2	2
147	Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis. Frontiers in Oncology, 2021, 11, 641044.	2.8	2
148	Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. Cureus, 2017, 9, e1517.	0.5	2
149	Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity Journal of Clinical Oncology, 2022, 40, 190-190.	1.6	2
150	Updated data from an ongoing study with ADP-A2AFP spear T-cells. Journal of Hepatology, 2020, 73, S910-S911.	3.7	1
151	Cermline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multi-center prospective study. Molecular Genetics and Metabolism, 2021, 132, S34-S35.	1.1	1
152	Recent advances in understanding cholangiocarcinoma. Faculty Reviews, 2020, 9, 15.	3.9	1
153	Preclinical evaluation of LCK as a novel therapeutic target in YAP-activated and FGFR2-altered cholangiocarcinoma Journal of Clinical Oncology, 2022, 40, 463-463.	1.6	1
154	Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. Cancer Investigation, 2016, 34, 57-63.	1.3	0
155	2-O, 3-O Desulfated Heparin (ODSH) May Mitigate Chemotherapy-Induced Thrombocytopenia and Neutropenia in Patients Treated with Combination Gemcitabine (G)/Nab-Paclitaxel (A), a Myelosuppressive Chemotherapy Regimen. Blood, 2012, 120, 4723-4723.	1.4	0
156	Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States. Hepatobiliary Surgery and Nutrition, 2020, 9, 501-504.	1.5	0
157	Recent advances in understanding cholangiocarcinoma. Faculty Reviews, 2020, 9, 15.	3.9	0
158	Reply to A. Rizzo et al. JCO Precision Oncology, 2022, 6, e2200061.	3.0	0